Swiss pharma giant Roche (ROG: SIX) announced the sector's biggest pharma M&A deal in October.
The month also saw two further deals announced by Eli Lilly (NYSE: LLY), making that six M&A deals this year revealed by the US pharma major.
Spending on pharma M&A in 2023 continues to outstrip the previous two years, with Pfizer's (NYSE: PFE) huge acquisition of Seagen (Nasdaq: SGN) making the former company the biggest spender in the sector so far this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze